COPD trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in COPD. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition BundleNCT06646419observationalTime to CID. | — | Active, not recruiting | 2026-08-31 | in 11 d | 2026-08-13 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary DiseaseNCT06531798To observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD | Phase 4 | Recruiting | 2026-10-30 | in 71 d | 2026-07-22 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation | Phase 3 | Active, not recruiting | 2026-12-01 | in 103 d | 2026-05-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in COPD
most recently updated first303 studies match. Showing the first 100 of 303 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMD | ResMed | $31.7B | HomeVent ( Connect) Registry: EU COPD Home NIV RegistryNCT02811588observationalPhase 1: Prevalence of hypercapnia in patients with GOLD stage 3 and 4 COPD. | — | Completed | Device: Non-invasive ventilation | Chronic Obstructive Pulmonary Disease | 169 | Jul 2016 | Dec 2024actual | — | 2026-08-14 |
| AZN | AstraZeneca | — | Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition BundleNCT06646419observationalTime to CID. | — | Active, not recruiting | — | COPD | 1,368 | 2024-11-13 | 2026-08-31 | in 11 d | 2026-08-13 |
| AZN | AstraZeneca | — | Study That Will Evaluate the Brazilian Population With COPD.NCT06780046observationalIncidence of hospitalizations | — | Recruiting | — | COPD (Chronic Obstructive Pulmonary Disease) | 693 | 2025-01-31 | 2027-09-30 | in 406 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738Annualised rate of moderate or severe COPD exacerbations | Phase 2 | Recruiting | Drug: AZD6793 · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 987 | 2025-06-27 | 2027-11-05 | in 442 d | 2026-08-11 |
| AZN | AstraZeneca | — | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. | Phase 3 | Completed | Drug: Placebo, Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | 1,454 | 2023-09-22 | 2026-03-06actual | — | 2026-07-24 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationNCT07073950Change from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI) | Phase 4 | Recruiting | Drug: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo · Device: Metered dose inhaler | Chronic Obstructive Pulmonary Disease, Hyperinflation | 56 | 2025-11-24 | 2027-05-31 | in 284 d | 2026-07-24 |
| AZN | AstraZeneca | — | Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary DiseaseNCT06531798To observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD | Phase 4 | Recruiting | Drug: Breztri Aerosphere | Moderate to Severe COPD | 150 | 2026-01-30 | 2026-10-30 | in 71 d | 2026-07-22 |
| AZN | AstraZeneca | — | This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabNCT06862206observationalasthma control questionnaire | — | Recruiting | Other: benralizumab | Chronic Obstructive Pulmonary Disease | 1,000 | 2025-07-11 | 2028-01-30 | in 528 d | 2026-07-22 |
| AZN | AstraZeneca | — | Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsNCT07566195Adverse events | Phase 3 | Recruiting | Drug: Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2 | Chronic Obstructive Pulmonary Disease, COPD | 59 | 2026-05-05 | 2028-12-29 | in 862 d | 2026-07-21 |
| UPB | Upstream Bio Inc. | $375M | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078Annualized rate of moderate or severe COPD exacerbation events | Phase 2 | Active, not recruiting | Drug: Verekitug · Other: Placebo | Chronic Obstructive Pulmonary Disease | 666 | 2025-07-02 | Oct 2027 | ≤ 437 d | 2026-07-20 |
| AZN | AstraZeneca | — | A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsNCT06897748Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic | Phase 2 | Completed | Drug: Placebo, Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | 98 | 2025-04-12 | 2026-04-21actual | — | 2026-07-14 |
| AZN | AstraZeneca | — | Study of Patient With Frequent COPD ExacerbationsNCT07221981observationalTo describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD. | — | Active, not recruiting | — | Chronic Obstructive Pulmonary Disease (COPD) | 2,038 | 2024-12-16 | 2026-06-30 | — | 2026-07-09 |
| SNY | Sanofi | — | The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryNCT07612878observationalParticipant Characteristics | — | Not yet recruiting | Drug: Cohort 1: Dupilumab · Other: Cohort 2: usual care only | COPD (Chronic Obstructive Pulmonary Disease) | 350 | 2026-07-31 | 2029-06-30 | in 1,045 d | 2026-07-02 |
| AZN | AstraZeneca | — | Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/TrixeoNCT07069829observationalchange from baseline in the COPD Assessment Test | — | Recruiting | — | Chronic Obstructive Pulmonary Disease | 1,400 | 2025-12-15 | 2027-09-30 | in 406 d | 2026-06-29 |
| AZN | AstraZeneca | — | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).NCT05742802Annualised rate of severe COPD exacerbations in former smokers. | Phase 3 | Completed | Combination product: Tozorakimab 1, Tozorakimab 2, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,713 | 2023-03-06 | 2026-02-26actual | — | 2026-06-25 |
| AZN | AstraZeneca | — | A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966Time to first severe cardiac or COPD event | Phase 3 | Recruiting | Drug: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg | COPD (Chronic Obstructive Pulmonary Disease) | 5,250 | 2024-02-21 | 2027-12-03 | in 470 d | 2026-06-24 |
| AZN | AstraZeneca | — | Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]NCT06511193observationalMean change from baseline in the COPD Assessment Test (CAT) score | — | Completed | Drug: Budenoside/Glycopyrronium/Formoterol | Chronic Obstructive Pulmonary Disease (COPD) | 152 | 2024-09-17 | 2026-05-05actual | — | 2026-06-24 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261Annualised rate of moderate or severe COPD exacerbations | Phase 3 | Recruiting | Biological: Tezepelumab · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 990 | 2025-03-25 | 2029-03-13 | in 936 d | 2026-06-24 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305Annualised rate of moderate or severe COPD exacerbations | Phase 3 | Recruiting | Biological: Tezepelumab · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 990 | 2025-03-18 | 2029-03-13 | in 936 d | 2026-06-24 |
| SNY | Sanofi | — | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations | Phase 3 | Recruiting | Drug: Lunsekimig, Placebo | Chronic Obstructive Pulmonary Disease | 942 | 2025-09-16 | 2029-11-27 | in 1,195 d | 2026-06-15 |
| SNY | Sanofi | — | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations | Phase 3 | Recruiting | Drug: Lunsekimig, Placebo | Chronic Obstructive Pulmonary Disease | 942 | 2025-09-17 | 2029-11-27 | in 1,195 d | 2026-06-15 |
| SNY | Sanofi | — | A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.NCT07053423Change from baseline to Week 24 in global lung mucus score (UCSF mucus scoring) | Phase 4 | Recruiting | Drug: Dupilumab, Placebo | Chronic Obstructive Pulmonary Disease | 218 | 2025-09-22 | 2028-12-23 | in 856 d | 2026-06-12 |
| AZN | AstraZeneca | — | A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese PopulationNCT06724848observationalMedical History | — | Recruiting | — | COPD | 850 | 2024-06-05 | 2027-10-21 | in 427 d | 2026-06-02 |
| AZN | AstraZeneca | — | Study of Patient With Frequent Exacerbations in MoscowNCT07307781observationalTo describe the baseline mean age of outpatients with COPD in Moscow. | — | Recruiting | — | Chronic Obstructive Pulmonary Disease (COPD) | 500 | 2025-11-28 | 2027-06-25 | in 309 d | 2026-05-29 |
| UTHR | United Therapeutics | $22.2B | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)NCT03794583results2023-12-18Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Inhaled treprostinil solution | Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | 41 | 2018-12-21 | 2022-11-29actual | — | 2026-05-27 |
| AZN | AstraZeneca | — | Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist DiagnosisNCT07245576observationalAccuracy of primary care asthma/COPD diagnosis using oscillometry (ALDS: R5, R20, R5-R20, X5, Ax) plus FeNO ≥50 ppb (Fenom PRO®/ALDS Pro) vs specialist gold standard; metrics: Cohen's kappa, agreement, sensitivity, specificity in overall, asthma, COPD | — | Recruiting | — | Asthma, COPD | 600 | 2025-12-26 | 2027-04-30 | in 253 d | 2026-05-27 |
| SNY | Sanofi | — | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo | Chronic Obstructive Pulmonary Disease | 700 | 2024-01-11 | 2026-12-01 | in 103 d | 2026-05-18 |
| REGN | Regeneron Pharmaceuticals | $76.1B | This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationNCT07587658Time to first all-cause event | Phase 4 | Not yet recruiting | Drug: dupilumab, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 754 | 2026-06-30 | 2028-07-30 | in 710 d | 2026-05-14 |
| AZN | AstraZeneca | — | BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREANCT07570394observationalIncidence proportion of Adverse Events (AEs)/Adverse Drug Reactions (ADRs) | — | Not yet recruiting | — | Chronic Obstructive Pulmonary Disease (COPD) | 600 | 2026-07-31 | 2027-07-31 | in 345 d | 2026-05-06 |
| AZN | AstraZeneca | — | MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiANCT06422676observationalChange in COPD Assessment Test (CAT) score | — | Completed | — | Chronic Obstructive Pulmonary Disease | 200 | 2023-12-29 | 2024-12-18actual | — | 2026-05-01 |
| AZN | AstraZeneca | — | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.NCT05158387Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. | Phase 3 | Completed | Drug: Tozorakimab, Tozorakimab, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,172 | 2022-02-07 | 2026-01-19actual | — | 2026-04-16 |
| AZN | AstraZeneca | — | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT05166889Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. | Phase 3 | Completed | Drug: Tozorakimab, Tozorakimab, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,132 | 2022-01-03 | 2026-01-19actual | — | 2026-04-16 |
| SNY | Sanofi | — | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04701983Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) | Phase 3 | Completed | Drug: Itepekimab SAR440340, Placebo | Chronic Obstructive Pulmonary Disease | 1,127 | 2020-12-16 | 2025-04-11actual | — | 2026-04-15 |
| SNY | Sanofi | — | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04751487Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) in former smokers | Phase 3 | Completed | Drug: Itepekimab SAR440340, Placebo | Chronic Obstructive Pulmonary Disease | 1,239 | 2021-02-12 | 2025-04-21actual | — | 2026-04-15 |
| SNY | Sanofi | — | Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported OutcomesNCT07380711observationalDescriptive statistical analysis of socio-demographics | — | Recruiting | — | Chronic Obstructive Pulmonary Disease COPD | 500 | 2026-01-28 | 2030-08-14 | in 1,455 d | 2026-04-14 |
| AZN | AstraZeneca | — | Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)NCT05862545observationalCOPD Assessment Test (CAT) score | — | Completed | Drug: BGF (budesonide/glycopyrrolate/formoterol fumarate) | Chronic Obstructive Pulmonary Disease | 250 | 2023-06-01 | 2025-05-31actual | — | 2026-03-18 |
| AZN | AstraZeneca | — | EXACOS EG PopulationNCT06983340observationalTo estimate the frequency of severe AECOPD in COPD population in Egypt | — | Withdrawnsponsor's stated reason: Study withdrawn since it was rejected by local regulatory authority. | — | Chronic Obstructive Pulmonary Disease | 0 | 2025-08-30 | 2025-12-31 | — | 2026-03-18 |
| LUNG | Pulmonx Corporation | $97M | An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe EmphysemaNCT06035120Converters, responder rate | Not applicable | Recruiting | Device: AeriSeal System | Emphysema, Pulmonary, Emphysema or COPD | 200 | 2024-02-22 | 2027-06-30 | in 314 d | 2026-03-13 |
| SNY | Sanofi | — | Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDNCT05326412Change from baseline in itepekimab pharmacodynamic normalized enrichment score (NES) derived from former smokers in endobronchial biopsies in current smokers with COPD | Phase 2 | Completed | Drug: Itepekimab SAR440340 | Chronic Obstructive Pulmonary Disease | 49 | 2022-05-19 | 2025-03-05actual | — | 2026-03-11 |
| AZN | AstraZeneca | — | A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).NCT06067828Change from baseline in isotime Inspiratory capacity (IC) | Phase 3 | Completed | Drug: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo | Chronic Obstructive Pulmonary Disease | 171 | 2023-10-24 | 2026-01-22actual | — | 2026-03-05 |
| LUNG | Pulmonx Corporation | $97M | Zephyr Etude Post-Inscription (French Registry)NCT04517916observationalForced Expiratory Volume in 1 second (FEV1) | — | Completed | Device: Zephyr Valve | Emphysema or COPD | 155 | 2021-01-04 | 2022-06-22actual | — | 2026-02-18 |
| AZN | AstraZeneca | — | Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe ExacerbationNCT07414134observationalAnnualized COPD Exacerbation Event Rate | — | Completed | Drug: BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL | Chronic Obstructive Pulmonary Disease | 3,598 | 2025-10-31 | 2025-11-28actual | — | 2026-02-17 |
| AZN | AstraZeneca | — | Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlDNCT06368427observationalChange from baseline to 12 weeks (3 months) in the COPD Assessment Test (CAT) score | — | Completed | Drug: budesonide / glycopyrronium / formoterol | Chronic Obstructive Pulmonary Disease (COPD) | 10 | 2024-04-30 | 2025-11-17actual | — | 2025-12-22 |
| SNY | Sanofi | — | Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world ConditionsNCT07052396observationalChange from Baseline in COPD Assessment Test (CAT) Score | — | Recruiting | Drug: Dupilumab | Chronic Obstructive Pulmonary Disease (COPD) | 350 | 2025-07-01 | 2029-07-01 | in 1,046 d | 2025-12-22 |
| AZN | AstraZeneca | — | Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.NCT06321731observationalAnnualized rate of exacerbations after BGF initiation | — | Completed | — | Chronic Obstructive Pulmonary Disease (COPD) | 718 | 2024-07-02 | 2024-12-16actual | — | 2025-11-28 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseNCT05292950Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor business decision | Drug: ARO-MUC5AC, Placebo | Asthma, Chronic Obstructive Pulmonary Disease | 78 | 2022-06-27 | 2024-11-12actual | — | 2025-11-05 |
| GENB | Generate Biomedicines | $2.0B | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDNCT07116889Number of participants with treatment related adverse events as assessed by CTCAE 5.0 | Phase 1 | Active, not recruiting | Biological: GB-0895 (SC), GB-0895 (SC) · Drug: Placebo (SC), Placebo (SC) | Asthma, COPD (Chronic Obstructive Pulmonary Disease) | 156 | 2023-12-12 | May 2027 | ≤ 284 d | 2025-11-05 |
| HBC.OL | Hofseth Biocare ASA | — | Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary DiseaseNCT05130294Level of oxidative low-density lipoprotein (ox-LDL) | Not applicable | Withdrawnsponsor's stated reason: The study was terminated before recruitment began due to administrative decision. | Dietary supplement: CARDIO®, Placebo | Chronic Obstructive Pulmonary Disease | 0 | Jul 2025 | Nov 2026 | ≤ 102 d | 2025-09-26 |
| AZN | AstraZeneca | — | A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT05573464results2025-09-19Number and Percentage of Participants With Serious Adverse Events | Phase 3 | Completed | Drug: BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg | Chronic Obstructive Pulmonary Disease (COPD) | 559 | 2022-09-27 | 2024-03-26actual | — | 2025-09-19 |
| AZN | AstraZeneca | — | An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.NCT05492877results2025-08-29To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to Severe COPD. | Phase 2 | Completed | Drug: Mitiperstat (AZD4831) · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 381 | 2022-11-14 | 2024-08-12actual | — | 2025-08-29 |
| AZN | AstraZeneca | — | Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantNCT05477108results2025-05-28Maximum Observed Plasma (Peak) Drug Concentration (Cmax ) | Phase 1 | Completed | Drug: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) | Chronic Obstructive Pulmonary Disease | 108 | 2022-07-29 | 2023-04-11actual | — | 2025-08-28 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDNCT06075095Changes in FEV1 AUC (0-4) | Phase 3 | Completed | Drug: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA | COPD (Chronic Obstructive Pulmonary Disease) | 297 | 2024-01-11 | 2025-08-12actual | — | 2025-08-27 |
| AZN | AstraZeneca | — | A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantNCT05569421results2025-04-29Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf) | Phase 1 | Completed | Drug: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA | Chronic Obstructive Pulmonary Disease | 108 | 2022-10-11 | 2023-04-14actual | — | 2025-08-22 |
| AZN | AstraZeneca | — | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsNCT04053634Annualized rate of moderate or severe COPD exacerbations | Phase 3 | Completed | Biological: Benralizumab, Placebo | Chronic Obstructive Pulmonary Disease | 689 | 2019-08-26 | 2025-07-28actual | — | 2025-08-19 |
| AZN | AstraZeneca | — | A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a SpacerNCT06297668Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) of BGF MDI | Phase 1 | Completed | Drug: Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO · Device: AeroChamber Plus Flow-Vu spacer | Chronic Obstructive Pulmonary Disease | 42 | 2024-04-29 | 2024-06-11actual | — | 2025-08-13 |
| AZN | AstraZeneca | — | REported Outcomes in COPD With Trixeo in Real worlDNCT05213611observationalTo describe the change in COPD health status after 3 months of treatment vs baseline in eligible COPD patients initiated with TRIXEO treatment | — | Completed | — | Chronic Obstructive Pulmonary Disease | 150 | 2022-08-11 | 2024-07-08actual | — | 2025-07-11 |
| AZN | AstraZeneca | — | REported Outcomes in COPD With Trixeo in Real worlD in GermanyNCT05311306observationalChange from baseline in COPD Assessment Test (CAT) score after 3 months treatment | — | Completed | — | Chronic Obstructive Pulmonary Disease | 475 | 2022-03-15 | 2024-07-16actual | — | 2025-07-01 |
| SNY | Sanofi | — | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationNCT04456673results2025-03-17Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period | Phase 3 | Completed | Drug: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Chronic Obstructive Pulmonary Disease | 935 | 2020-07-06 | 2024-02-28actual | — | 2025-05-29 |
| AZN | AstraZeneca | — | Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsNCT03022097results2025-03-26Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) | Phase 3 | Completed | Drug: Aclidinium bromide/formoterol Fixed-Dose Combination, Aclidinium bromide, Formoterol Fumarate, Placebo | COPD | 1,625 | 2017-02-02 | 2022-04-14actual | — | 2025-03-26 |
| AZN | AstraZeneca | — | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic BronchitisNCT04631016results2025-02-27Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic | Phase 2 | Completed | Drug: Tozorakimab · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis | 137 | 2020-12-14 | 2023-05-30actual | — | 2025-02-27 |
| AZN | AstraZeneca | — | Tezepelumab COPD Exacerbation StudyNCT04039113results2025-02-18Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. | Phase 2 | Completed | Biological: Tezepelumab · Other: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 337 | 2019-07-30 | 2023-11-10actual | — | 2025-02-18 |
| AMGN | Amgen | $229.9B | A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00739648results2012-03-02Exacerbation Rate | Phase 2 | Completed | Drug: MP-376, Placebo | Chronic Obstructive Pulmonary Disease | 322 | Oct 2008 | Jan 2010actual | — | 2024-12-27 |
| TBPH | Theravance Biopharma | $880M | Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485results2024-12-20FEV1 | Phase 4 | Completed | Drug: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo | Chronic Obstructive Pulmonary Disease | 404 | 2022-01-07 | 2023-11-13actual | — | 2024-12-20 |
| LUNG | Pulmonx Corporation | $97M | Zephyr Valve Japan Post-Marketing SurveillanceNCT06332885observationalIncidence rate of pneumothorax at 45-days post-Zephyr Valve index procedure. | — | Recruiting | Device: Zephyr Endobronchial Valve | Emphysema, COPD, Severe Emphysema | 140 | 2024-03-12 | 2027-03-31 | in 223 d | 2024-12-13 |
| AMGN | Amgen | $229.9B | A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00752414Evaluate the safety, tolerability and PK of two dosage regimens of MP-376 | Phase 1 | Completed | Drug: MP-376 (Levofloxacin solution for Inhalation), Placebo | Chronic Obstructive Pulmonary Disease | 21 | Jul 2008 | Oct 2008actual | — | 2024-12-04 |
| LUNG | Pulmonx Corporation | $97M | Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)NCT04559464Percentage of subjects converted from a positive collateral ventilation status (CV+) to having little to no collateral ventilation (CV-) in the treated lobe. | Not applicable | Completed | Device: AeriSeal, Zephyr Valves | Emphysema, COPD, Severe Emphysema | 102 | 2020-12-15 | 2023-10-24actual | — | 2024-11-04 |
| AZN | AstraZeneca | — | Observational Study of Obstructive Lung Disease (NOVELTY)NCT02760329observationalSpirometry - change in Forced Expiratory Volume in 1 second (FEV1) (Litres [L]) | — | Completed | Procedure: Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO) | Asthma, COPD, Chronic Obstructive Pulmonary Disease | 12,255 | 2016-07-25 | 2023-05-31actual | — | 2024-10-03 |
| SNY | Sanofi | — | Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled SyringeNCT06114238Assessment of pharmacokinetic (PK) parameter of itepekimab: Cmax | Phase 1 | Completed | Drug: Itepekimab AI, Itepekimab PFS | Chronic Obstructive Pulmonary Disease | 90 | 2021-09-16 | 2022-03-08actual | — | 2024-09-19 |
| PFE | Pfizer | $155.3B | Immunization To Prevent Acute COPD ExacerbationsNCT03276754results2024-08-19observationalChange in Adjusted Rate of Moderate/Severe COPD Exacerbations at Month 24 in PCV 13 Population | — | Terminatedsponsor's stated reason: The study was terminated prematurely due to the inability to recruit the planned number of subjects and the interim analysis indicated that the number of included patients did not allow draw any valid conclusion about the main objective of the study | — | Pneumococcal Infections, COPD | 530 | 2017-11-30 | 2022-06-16actual | — | 2024-08-19 |
| AZN | AstraZeneca | — | The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap PatientsNCT04905420observationalIncidence rate of newly diagnosed | — | Completed | — | Asthma, COPD, Asthma-COPD Overlap | 288,538 | 2021-12-08 | 2023-06-12actual | — | 2024-07-31 |
| AZN | AstraZeneca | — | Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical PracticeNCT04536402observationalIncidence of all AEs /SAEs | — | Completed | — | Chronic Obstructive Pulmonary Disease | 3,520 | 2021-03-16 | 2023-11-08actual | — | 2024-07-29 |
| OGN | Organon and Co | $3.6B | Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)NCT00383721results2011-10-26Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,196 | Sep 2006 | Jul 2010actual | — | 2024-05-23 |
| OGN | Organon and Co | $3.6B | Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)NCT00383435results2011-10-03Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,055 | Oct 2006 | Jul 2010actual | — | 2024-05-20 |
| OGN | Organon and Co | $3.6B | A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)NCT00604500results2011-04-12Overall Discrepancy Rate | Phase 3 | Completed | Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | Asthma, COPD | 272 | 2008-03-01 | 2008-11-01actual | — | 2024-05-20 |
| AZN | AstraZeneca | — | Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)NCT05903989observationalProportion of patients with CAT (≥10, <10) at registration in each inhaler treatment group (Long acting muscarinic antagonist(LAMA), LAMA+Long acting β2 agonist(LABA) or Inhaled corticosteroid(ICS) +LABA) | — | Completed | — | COPD | 708 | 2023-09-11 | 2023-10-24actual | — | 2024-05-10 |
| SNY | Sanofi | — | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationNCT03930732results2024-02-28Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period | Phase 3 | Completed | Drug: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Chronic Obstructive Pulmonary Disease | 939 | 2019-04-15 | 2023-02-08actual | — | 2024-02-28 |
| AZN | AstraZeneca | — | IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the USNCT05970263Proportion of patients with an all-cause readmission | Phase 4 | Withdrawnsponsor's stated reason: Recruitment challenges | Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily. · Other: External Comparator | COPD | 0 | 2024-01-19 | 2025-12-31 | — | 2024-02-01 |
| UTHR | United Therapeutics | $22.2B | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)NCT03496623results2023-11-24Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD) | Phase 3 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Inhaled treprostinil solution, Placebo solution | Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | 188 | 2018-05-08 | 2022-10-13actual | — | 2023-11-24 |
| AZN | AstraZeneca | — | Exacerbations and Their Outcomes International (EXACOS International)NCT04928417observationalEstimate the frequency of severe Acute exacerbation of COPD, in a COPD population | — | Completed | — | Chronic Obstructive Pulmonary Disease | 1,762 | 2021-11-26 | 2022-11-30actual | — | 2023-10-18 |
| AZN | AstraZeneca | — | Long-term Observational Study of the Safety of RoflumilastNCT03381573observationalAll-cause mortality | — | Completed | Drug: Roflumilast | COPD | 135,856 | 2013-12-15 | 2022-09-16actual | — | 2023-09-26 |
| MREO | Mereo BioPharma | $250M | Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationNCT01332097results2023-03-21Change in FEV1 From Baseline to Day 5 or Baseline to Day 10 Measure: FEV1 Change in Forced Expiry Volume in 1 Second | Phase 2 | Completed | Drug: BCT197, Prednisone placebo, BCT197 placebo, Prednisone | Chronic Obstructive Pulmonary Disease | 183 | Mar 2011 | May 2013actual | — | 2023-03-21 |
| AZN | AstraZeneca | — | A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and FormoterolNCT04600505results2023-01-23Maximum Observed Concentration (Cmax) of BGF MDI | Phase 1 | Completed | Drug: Treatment A, Treatment B, Treatment C | Chronic Obstructive Pulmonary Disease (COPD) | 47 | 2020-10-19 | 2021-05-17actual | — | 2023-01-23 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)NCT04441788results2022-12-20Change From Baseline to the Primary Time Point in Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo | Phase 2 | Terminatedsponsor's stated reason: Business Decision to Terminate Study | Drug: ION-827359, Placebo, ION-827359 | Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | 60 | 2020-12-22 | 2021-04-27actual | — | 2022-12-20 |
| SNY | Sanofi | — | Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)NCT03546907results2022-11-22Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants | Phase 2 | Completed | Drug: SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care | Chronic Obstructive Pulmonary Disease | 343 | 2018-07-16 | 2019-10-03actual | — | 2022-11-22 |
| SR | Spire, Inc. | $4.9B | Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD PatientsNCT05518981observationalAll-Cause Hospitalizations | — | Completed | Device: Respiratory Remote Patient Monitor (Spire Health Tag) | Chronic Obstructive Pulmonary Disease | 126 | 2019-05-01 | 2022-02-28actual | — | 2022-08-29 |
| PULM | Pulmatrix Inc. | $6M | A Phase 1b Study of PUR1800 in Patients With COPDNCT04759807Incidence of treatment-emergent adverse events adult patients with stable COPD. | Phase 1 | Completed | Drug: Placebo Comparator, PUR1800 250 ug, PUR1800 500 ug | Chronic Obstructive Pulmonary Disease (COPD) | 18 | 2021-01-04 | 2021-12-02actual | — | 2022-06-27 |
| MREO | Mereo BioPharma | $250M | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.NCT03636347Change from baseline on blood biomarkers of neutrophil elastase activity compared to baseline and placebo | Phase 2 | Completed | Drug: Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2 | Alpha 1-Antitrypsin Deficiency, Emphysema, COPD | 99 | 2018-10-29 | 2022-03-02actual | — | 2022-04-14 |
| AZN | AstraZeneca | — | Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.NCT04078126results2022-03-18Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment | Phase 3 | Completed | Combination product: BFF, Symbicort Turbuhaler | Chronic Obstructive Pulmonary Disease (COPD) | 35 | 2019-09-10 | 2020-12-30actual | — | 2022-03-18 |
| RMD | ResMed | $31.7B | Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)NCT03513068results2022-02-16Physical Activity Level | Not applicable | Terminatedsponsor's stated reason: COVID-19 | Device: Portable Oxygen Concentrator (POC) | COPD | 108 | 2018-07-24 | 2020-09-02actual | — | 2022-02-16 |
| AZN | AstraZeneca | — | Realize the Current Situation of COPD Patients in ChinaNCT03131362observationalThe mean rate of COPD exacerbations | — | Completed | — | Chronic Obstructive Pulmonary Disease COPD | 5,020 | 2017-06-30 | 2020-08-06actual | — | 2022-01-26 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPDNCT00457951results2016-12-16Incidence of Treatment Failure | Phase 2 | Terminatedsponsor's stated reason: Interim analysis: safety without efficacy ODSH in patients with acute COPD. | Drug: Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH | Chronic Obstructive Pulmonary Disease | 158 | Apr 2007 | Aug 2009actual | — | 2021-12-02 |
| RMD | ResMed | $31.7B | Juno Perth Clinical TrialNCT02317042results2021-06-08Apnoea-Hypopnoea Index (AHI) | Not applicable | Terminatedsponsor's stated reason: Phase II not initiated for commercial reasons (no safety related issues) | Device: Juno, Juno, Juno | Respiratory Insufficiency, Obesity Hypoventilation Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Disease, Upper Airway Obstruction | 25 | 2015-05-29 | Nov 2015actual | — | 2021-06-08 |
| RMD | ResMed | $31.7B | Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)NCT04107493results2021-05-26Mean SpO2 (Oxygen Saturation) During Six Minute Walk Tests (6MWTs) | Not applicable | Completed | Device: Portable Oxygen Cylinder, Mobi | Chronic Obstructive Pulmonary Disease | 33 | 2019-11-21 | 2020-03-09actual | — | 2021-05-26 |
| RMD | ResMed | $31.7B | Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory FailureNCT01174316pH at 1+ hour | Not applicable | Withdrawnsponsor's stated reason: difficulty recruiting | Device: AutoVPAP™, VPAPIIIST-A™ | Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome | 0 | Aug 2010 | 2011-03-01actual | — | 2021-04-19 |
| AZN | AstraZeneca | — | A Scintigraphy Study of PT010 in COPD PatientsNCT03906045The percentage (%) emitted dose of radiolabelled BGF MDI deposited in the lungs following a maximal breath-hold of up to 10 s. | Phase 1 | Completed | Drug: BGF-MDI | Chronic Obstructive Pulmonary Disease | 18 | 2019-04-04 | 2020-03-05actual | — | 2021-02-12 |
| AZN | AstraZeneca | — | A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPDNCT03836677results2021-02-11Specific Image-based Airway Volume (siVaw) | Phase 3 | Completed | Combination product: BGF, GFF | Chronic Obstructive Pulmonary Disease (COPD) | 23 | 2019-02-26 | 2019-11-11actual | — | 2021-02-11 |
| SR | Spire, Inc. | $4.9B | An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD SubjectsNCT03745547observationalSpire wearable health monitor physiological data collection | — | Completed | Other: Adherence to wearing a Spire wearable health monitor | Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease | 184 | 2018-11-20 | 2020-04-10actual | — | 2021-01-15 |
| NVS | Novartis | — | Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary DiseaseNCT00532350Forced expiratory volume in 1 second | Phase 1 | Completed | Drug: QAT370, Placebo, Tiotropium | Chronic Obstructive Pulmonary Disease | 22 | Jul 2007 | — | — | 2020-12-19 |
| AZN | AstraZeneca | — | A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.NCT03645434results2020-12-17Change From Baseline in Trough FEV1 at Day 15 | Phase 2 | Completed | Drug: AZD8871, Anoro® Ellipta® | Chronic Obstructive Pulmonary Disease | 73 | 2018-10-10 | 2019-08-07actual | — | 2020-12-17 |
| GILD | Gilead Sciences | $177.9B | Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)NCT02077465results2020-08-13Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Phase 1 | Completed | Drug: Andecaliximab, Placebo to match Andecaliximab | Chronic Obstructive Pulmonary Disease | 11 | 2014-03-11 | 2014-10-27actual | — | 2020-09-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How COPD is matched — 14 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Chronic Obstructive Pulmonary Disease
- Chronic Obstructive Pulmonary Disease (COPD)
- COPD
- Chronic Obstructive Pulmonary Disease COPD
- COPD (Chronic Obstructive Pulmonary Disease)
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- COPD Exacerbation
- Chronic Obstructive Airway Disease
- Chronic Obstructive Pulmonary Disease - COPD
- Chronic Obstructive Pulmonary Disease, COPD
- Emphysema or COPD
- Moderate Chronic Obstructive Pulmonary Disease
- Moderate to Severe COPD
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “COPD” (a text search, wider than this page)